14 results about "Lipogenesis" patented technology

Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and / or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

The present application relates to inhibitors, compositions comprising inhibitors and their use in the treatment or prevention of metabolic diseases or disorders, such as metabolic diseases or disorders associated with non-alcoholic fatty liver (NAFLD), and / or obesity, and / or diseases or disorders associated with adipogenesis.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The invention provides application of an SLC13A3 gene serving as a target spot in preparation of a medicine for treating metabolism-related fatty liver diseases. By constructing an MASLD cell model and an MASLD mouse model with the lesion degree from light to heavy, the expression of the SLC13A3 in the liver tissue and cell model of the metabolism-related fatty liver disease mouse is up-regulated, and the up-regulation multiple is gradually increased along with the increase of the severity of the disease. Animal experiments show that the liver specific knock-down SLC13A3 can significantly relieve weight and liver weight increase, liver fatty degeneration, liver lipid accumulation and liver function impairment accompanied by MASLD, and reduce the expression of adipogenesis genes. The invention provides a new target and a new thought for the development of drugs for treating metabolism-related fatty liver diseases.

The invention relates to the technical field of molecular biology, in particular to siRNA for interfering LRP6 as well as a product and application thereof. The nucleotide sequence of the siRNA for interfering with the LRP6 is shown as SEQ ID NO.1-8. The invention also discloses a preparation method of the siRNA. After an interference fragment of the LRP6 is obtained through screening, cell transfection is carried out, the LRP6 is interfered through siRNA, it is revealed that the interference LRP6 significantly inhibits the activity of subpigskin precursor fat cells and promotes differentiation and adipogenesis of the subpigskin precursor fat cells, it is revealed that the LRP6 can positively regulate and control proliferation of the subpigskin precursor fat cells and negatively regulate and control adipogenesis, a reference is provided for optimizing the pig fat deposition efficiency, and the application of the LRP6 in the field of pig fat deposition is provided. Effective functional genes are provided for pork quality character breeding, and effective targets are provided for high-quality pork pigs.

The invention relates to the technical field of biology, in particular to application of a PHB2 protein or a coding gene of the PHB2 protein in preparation of a medicine for regulating and controlling adipogenesis. The invention discovers that the PHB2 protein, the encoding gene of the PHB2 protein or the biological material containing the encoding gene can regulate and control the adipogenesis for the first time, and the effect of inhibiting the adipogenesis is achieved by improving the activity of the PHB2 protein or improving the expression quantity of the encoding gene. Therefore, the PHB2 protein and the encoding gene of the PHB2 protein can be used as a target for preparing a medicine for regulating and controlling adipogenesis, a medicine for treating animal obesity and a product for regulating and controlling adipocyte differentiation, and can also be used as a target for screening the medicine for regulating and controlling the adipogenesis. The invention provides a new technical scheme for solving the problem of chicken abdominal fat deposition.

The present invention relates to a composition for regulating hepatic lipid metabolism, comprising Lactiplantibacillus plantarum OPT-A1 strain deposited under accession number KCTC 15555BP, a culture liquid thereof, a cultured product thereof, or a culture lysate thereof. The composition suppresses lipid accumulation and expression of genes related to lipogenesis in hepatocytes, and enhances expression of genes related to lipid oxidation. In addition, the composition inhibits accumulation of triglycerides in hepatocytes and reduces blood triglyceride levels, total cholesterol levels, and liver injury indices. Furthermore, the composition promotes rapid consumption of lipids in hepatocytes and somatic cells through enhancement of muscle mass, and thus can be advantageously used as a raw material for foods, pharmaceuticals, and the like related to alleviation and treatment of various metabolic diseases.

The invention discloses application of a peptide MPM in lipid generation, and belongs to the technical field of biological medicines. The peptide MPM can promote lipid generation, so that the peptide MPM and a reagent for promoting the content of the peptide MPM can be used for preparing a reagent or a medicine for promoting lipid generation, an inhibitor of the peptide MPM or a reagent for reducing the content of the peptide MPM can be used for preparing a reagent or a medicine for inhibiting lipid generation, and the peptide MPM has a relatively great application prospect.

The human umbilical cord MSCs knocked down and expressing the METTL1 gene are constructed through lentivirus infection, secretion of NAMPT can be promoted, SIRT1 can be activated, accordingly, an SREBP1-mediated adipogenesis gene is inhibited, liver cell lipid accumulation is remarkably reduced in in-vitro and in-vivo MASLD models, and metabolic dysfunction related fatty liver diseases and insulin resistance are improved and treated.

The present invention relates to inhibitors, and compositions comprising the inhibitors, and their use in the treatment or prevention of metabolic diseases or disorders, such as metabolic diseases or disorders associated with non-alcoholic fatty liver disease (NAFLD), and / or diseases or disorders associated with obesity and / or lipogenesis.

Cosmetic system, comprehensive (a) a serum containing a peptide signaling complex which includes at least one peptide or peptide derivative which - stimulates the differentiation, lipogenesis or proliferation of adipocytes or - modulates matrix communication between dermis and subcutis, or - both effects combined, and (b) a lamellar cream with skin-identical lipid lamellae (phosphatidylcholine, ceramides, cholesterol, free fatty acids) for fixation and transduction of the peptides applied under (a); for cosmetic use to maintain and regenerate subcutaneous adipose tissue and dermal support structure.

The invention relates to the technical field of cosmetics, in particular to a composition for relieving local cellulite, cosmetics and a preparation method. The composition comprises 1-10% of a silybum marianum extract; 1 to 10% of tripeptide-3; 1 to 5% of glaucine; and 0.1-5% of a papaver rhoeas extract. The composition can promote fat decomposition in adipocytes, inhibit fat formation, induce white adipocytes to generate NRG4, promote browning of the white adipocytes and convert the white adipocytes into beige adipocytes, and reduce the content of the adipocytes. The glaucine and the silybum marianum extract jointly improve microcirculation and relieve edema, and a better environment is created for fat metabolism. The tripeptide-3 directly acts on fat cells to promote lipolysis. The corn poppy extract reinforces the skin structure above and prevents fat from protruding. The improved circulation not only contributes to carrying away free fatty acids decomposed from tripeptide-3, but also can promote nutrient substances to be conveyed to fibroblasts to synthesize collagen.

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

The present invention relates to a composition for the prevention, improvement, or treatment of obesity or obesity-induced inflammation comprising patulin as an active ingredient. A composition containing patulin as an active ingredient according to the present invention has the effect of inhibiting lipid accumulation, and can inhibit lipid accumulation by regulating sugar absorption, glycerol excretion, or LDL absorption, reducing the expression of factors related to lipogenesis or lipid synthesis such as Pparγ, Fasn, Acly, C / ebpα, Fabp4, Cd36, Dgat2, or Gpat, increasing the expression of fatty acid oxidation regulators such as PGC1α or CPT1a, and improving the volume and membrane potential of mitochondria. In addition, it can inhibit the expression of pro-inflammatory cytokines or inflammatory regulators such as IL-6, TNF-α, iNOS, or Cox-2, thereby preventing, treating, or improving obesity or obesity-induced inflammation, and can be utilized as a material for food, feed, pharmaceuticals, quasi-pharmaceuticals, etc.